Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...

Descripción completa

Detalles Bibliográficos
Autores principales: Votavova, Hana, Urbanova, Zuzana, Kundrat, David, Dostalova Merkerova, Michaela, Vostry, Martin, Hruba, Monika, Cermak, Jaroslav, Belickova, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825690/
https://www.ncbi.nlm.nih.gov/pubmed/33430232
http://dx.doi.org/10.3390/ph14010041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825690/
https://www.ncbi.nlm.nih.gov/pubmed/33430232
http://dx.doi.org/10.3390/ph14010041

Ejemplares similares